Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.66 |
| ▸ | IDO1 | P14902 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL750261 | 0.87 | MEN1 (0.58) | MEN1KMT2ACYP2C19CYP19A1IDO1 | |
| SCHEMBL1876581 | 0.86 | IDO1 (0.70) | CYP2C19IDO1MAPTSMN1; SMN2LMNA | |
| SCHEMBL1581598 | 0.85 | CYP2C19 (0.67) | CYP2C19CYP19A1IDO1MAPTSMN1; SMN2 | |
| SCHEMBL10638309 | 0.85 | CYP2C19 (0.67) | MEN1KMT2ACYP2C19IDO1MAPT | |
| SCHEMBL7011027 | 0.85 | ALDH1A1 (0.74) | KMT2ACYP2C19CYP19A1IDO1MAPT | |
| SCHEMBL15310921 | 0.84 | NAMPT (0.78) | MEN1KMT2A | |
| SCHEMBL25011257 | 0.83 | IDO1 (0.58) | MEN1KMT2ACYP2C19CYP19A1IDO1 | |
| SCHEMBL1169297 | 0.82 | NAMPT (0.72) | CYP2C19CYP19A1IDO1MAPTSMN1; SMN2 | |
| SCHEMBL5646684 | 0.82 | PAX8 (0.64) | CYP2C19IDO1MAPTSMN1; SMN2LMNA | |
| SCHEMBL15067289 | 0.81 | IDO1 (0.64) | MEN1KMT2ACYP2C19IDO1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6946473-B2 | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors | WYETH HOLDINGS CORPORATION (US) | 2005-09-20 | — | — | US | disclosed |
| US-20030208066-A1 | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors | AMERICAN CYANAMID COMPANY | 2003-11-06 | — | — | US | disclosed |
| EP-1279674-A2 | Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors | American Cyanamid Company (US) | 2003-01-29 | — | — | EP | disclosed |
| EP-1157024-B1 | ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS | AMERICAN CYANAMID CO (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-1157024-A1 | ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS | American Cyanamid Company (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000044749-A1 | ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030208066-A1 | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors | SI, TNF, PTDSS1 | MEN1 2211/4885KMT2A 3583/4885CYP2C19 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.